287 related articles for article (PubMed ID: 25567681)
1. Protease Inhibitors and Renal Function in Patients with HIV Infection: a Systematic Review.
Bagnis CI; Stellbrink HJ
Infect Dis Ther; 2015 Jan; 4(1):15-50. PubMed ID: 25567681
[TBL] [Abstract][Full Text] [Related]
2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
3. An overview of tenofovir and renal disease for the HIV-treating clinician.
Venter WDF; Fabian J; Feldman C
South Afr J HIV Med; 2018; 19(1):817. PubMed ID: 30167339
[TBL] [Abstract][Full Text] [Related]
4. Systematic review of renal and bone safety of the antiretroviral regimen efavirenz, emtricitabine, and tenofovir disoproxil fumarate in patients with HIV infection.
Bedimo R; Rosenblatt L; Myers J
HIV Clin Trials; 2016 Nov; 17(6):246-266. PubMed ID: 27809711
[TBL] [Abstract][Full Text] [Related]
5. Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.
Suzuki S; Nishijima T; Kawasaki Y; Kurosawa T; Mutoh Y; Kikuchi Y; Gatanaga H; Oka S
AIDS Patient Care STDS; 2017 Mar; 31(3):105-112. PubMed ID: 28282247
[TBL] [Abstract][Full Text] [Related]
6. Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Gianotti N; Galli L; Poli A; Salpietro S; Nozza S; Carbone A; Merli M; Ripa M; Lazzarin A; Castagna A
Medicine (Baltimore); 2016 May; 95(22):e3780. PubMed ID: 27258510
[TBL] [Abstract][Full Text] [Related]
7. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial.
DeJesus E; Rockstroh JK; Henry K; Molina JM; Gathe J; Ramanathan S; Wei X; Yale K; Szwarcberg J; White K; Cheng AK; Kearney BP;
Lancet; 2012 Jun; 379(9835):2429-2438. PubMed ID: 22748590
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
Cvetkovic RS; Goa KL
Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
[TBL] [Abstract][Full Text] [Related]
9. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
Pontrelli G; Cotugno N; Amodio D; Zangari P; Tchidjou HK; Baldassari S; Palma P; Bernardi S
BMC Infect Dis; 2012 Jan; 12():18. PubMed ID: 22269183
[TBL] [Abstract][Full Text] [Related]
10. Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.
Achhra AC; Nugent M; Mocroft A; Ryom L; Wyatt CM
Curr HIV/AIDS Rep; 2016 Jun; 13(3):149-57. PubMed ID: 27130284
[TBL] [Abstract][Full Text] [Related]
11. Evolution of renal function in African patients initiating second-line antiretroviral treatment: findings from the ANRS 12169 2LADY trial.
Cournil A; Hema A; Eymard-Duvernay S; Ciaffi L; Badiou S; Kabore FN; Diouf A; Ayangma L; Le Moing V; Reynes J; Koulla-Shiro S; Delaporte E;
Antivir Ther; 2017; 22(3):195-203. PubMed ID: 27705950
[TBL] [Abstract][Full Text] [Related]
12. Brief Report: Tenofovir-Associated Nephrotoxicity Among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals.
LaFleur J; Bress AP; Esker S; Knippenberg K; Crook J; Nyman H; Bedimo R; Tebas P; Rosenblatt L
J Acquir Immune Defic Syndr; 2018 Mar; 77(3):325-330. PubMed ID: 29210830
[TBL] [Abstract][Full Text] [Related]
13. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Mocroft A; Lundgren JD; Ross M; Fux CA; Reiss P; Moranne O; Morlat P; Monforte Ad; Kirk O; Ryom L;
Lancet HIV; 2016 Jan; 3(1):e23-32. PubMed ID: 26762990
[TBL] [Abstract][Full Text] [Related]
14. Darunavir: a review of its use in the management of HIV infection in adults.
McKeage K; Perry CM; Keam SJ
Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
[TBL] [Abstract][Full Text] [Related]
15. Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Shey MS; Kongnyuy EJ; Alobwede SM; Wiysonge CS
Cochrane Database Syst Rev; 2013 Mar; 2013(3):CD005481. PubMed ID: 23543540
[TBL] [Abstract][Full Text] [Related]
16. Renal function with use of a tenofovir-containing initial antiretroviral regimen.
Gallant JE; Moore RD
AIDS; 2009 Sep; 23(15):1971-5. PubMed ID: 19696652
[TBL] [Abstract][Full Text] [Related]
17. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy.
Goicoechea M; Liu S; Best B; Sun S; Jain S; Kemper C; Witt M; Diamond C; Haubrich R; Louie S;
J Infect Dis; 2008 Jan; 197(1):102-8. PubMed ID: 18171292
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
Sharma P; Blackburn RC; Parke CL; McCullough K; Marks A; Black C
Cochrane Database Syst Rev; 2011 Oct; (10):CD007751. PubMed ID: 21975774
[TBL] [Abstract][Full Text] [Related]
19. Health Care Costs in a Cohort of HIV-Infected U.S. Veterans Receiving Regimens Containing Tenofovir Disoproxil Fumarate/Emtricitabine.
Nelson RE; Ma J; Crook J; Knippenberg K; Nyman H; Paul D; Esker S; LaFleur J
J Manag Care Spec Pharm; 2018 Oct; 24(10):1052-1066. PubMed ID: 30247099
[TBL] [Abstract][Full Text] [Related]
20. Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease.
Mizushima D; Nguyen DTH; Nguyen DT; Matsumoto S; Tanuma J; Gatanaga H; Trung NV; van Kinh N; Oka S
J Infect Chemother; 2018 Jul; 24(7):549-554. PubMed ID: 29602711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
